HOME >> BIOLOGY >> NEWS
Failure to dispose of unneeded cells during development linked to cancer

A new research study reveals that a diverse group of apparently unrelated genes that are associated with pheochromocytoma intersect at a common pathway that drives the necessary culling of cells. Mutations in these genes disrupt the normal disposal of unneeded or damaged cells during development, thereby allowing potentially dangerous premalignant cells that should not have survived to persist. The mechanism described in the work, published in the August issue of Cancer Cell, may play a role in other forms of pediatric and hereditary cancer as well.

Pheochromocytomas are tumors that are derived from neural crest cells, which also give rise to the sympathetic nervous system. Inherited cases of pheochromocytoma are associated with mutations in a group of very dissimilar genes, presenting an intriguing puzzle as to how disruption of such different genes could cause the same disease. Further, noninherited somatic pheochromocytomas rarely exhibit mutations in the same genes that have been linked to the familial cancer. Dr. William G. Kaelin, Jr. from the Dana-Farber Cancer Institute and Brigham and Women's Hospital and colleagues found that all the genetic lesions associated with inherited pheochromocytomas result in a reduction of programmed cell death, called apoptosis, during development.

The researchers show that mutations in each of the disparate genes that cause familial pheochromocytoma, NF1, c-RET, SDH, and VHL, ultimately can interfere with the normal activity of EglN3, an enzyme that is required for apoptosis during development. Reduced apoptosis results in sympathetic neuronal progenitors that can elude developmental apoptosis and have a high risk of becoming cancerous later on. These results explain why NF1, c-RET, SDH, and VHL mutations are rare in somatic pheochromocytomas because mutations in these genes would no longer cause problems after the developmental window during which apoptosis occurs had passed. The authors speculate that
'"/>

Contact: Heidi Hardman
hhardman@cell.com
1-617-397-2879
Cell Press
15-Aug-2005


Page: 1 2

Related biology news :

1. Failure to meet United Nations sanitation target could affect millions of the worlds poorest
2. Failure of scout cells may lead to cancer in transplant patients
3. Unstable leukemia stem cells may predispose patients to drug resistance
4. Stanford-led study closes in on genes that may predispose some people to severe depression
5. Researchers develop alternate method to dispose nuclear liquid waste
6. Newly created cancer stem cells could aid breast cancer research
7. ESF EURYI award winner aims to stop cancer cells reading their own DNA
8. OHSU turns mouse into factory for human liver cells
9. UCLA scientists produce functioning neurons from human embryonic stem cells
10. UCF research links proteins, stem cells and potential Alzheimers treatment
11. Teamwork between 2 key proteins necessary for normal development and regulation of red blood cells

Post Your Comments:
(Date:5/20/2013)... new study conducted at the University of Bristol and ... Biology sheds light on how the brain and ... from Bristol,s School of Earth Sciences, together with Tom ... the brains of 150 million year old dinosaurs. , ... dinosaur Dysalotosaurus lettowvorbecki : a very young (juvenile) ...
(Date:5/19/2013)... engineered a strain of electricity-producing bacteria that can grow ... carbon dioxide as its sole source of carbon. ... findings at the 113th General Meeting of the American ... of current production solely on hydrogen," says Amit Kumar, ... co-authors are part of the Lovley Lab Group at ...
(Date:5/18/2013)... today at Digestive Disease Week (DDW) explores new discoveries ... of coffee on autoimmune disease and palliative care for ... been associated with reduced risk of fibrosis, a new ... java each month also correlate with lower risk for ... Clinic, Rochester, MN, linked coffee consumption with reduced risk ...
Breaking Biology News(10 mins):Fossil brain teaser 2Coffee consumption associated with reduced risk of autoimmune liver disease 2
(Date:5/21/2013)... , May 21, 2013 ... Market Research ( http://www.transparencymarketresearch.com ) "Biochip Products and Services ... Tests) - U.S. Industry Analysis, Size, Share, Growth, Trends and Forecast, ... in 2011 and is expected to grow at a ... an estimated value of USD 4.7 billion in 2018. ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Revolutionary Science, ... automatic colony counter, announced today that they have expanded ... products , the IncuCount, IntelliCount, InCount and ImpressCount. ... sophistication are especially useful in food microbiology and pharmaceutical ... an updated look. A bright white enclosure with ...
(Date:5/21/2013)... MA (PRWEB) May 21, 2013 Possible mold ... And so, according to a report from eagletribune.com posted May ... mold. In case the result is positive, My Cleaning Products ... using harmful chemical ingredients. , It was said in the ... re-infestation in the campus sparked after a first-grade classroom ...
Breaking Biology Technology:The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 2Possible Mold Re-infestation Gets Guilmette School Scheduled for Re-inspection, My Cleaning Products Offers Tip How to Kill Mold Safely If Inspection Turns Positive 3
Cached News: